← Leaderboards
Ronald C Desrosiers
Harvard University (Medical School)
$52,941,615
Attributed
$52,941,615
Total exposure
69
Grants
45
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.5M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$61,399,685 · 70
By mechanism
R01$19,393,215 · 6
P01$18,234,235 · 7
P51$10,010,579 · 50
R37$7,581,630 · 2
U19$5,409,943 · 2
R56$604,524 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard University (Medical School)
Same institution · by research overlap
- Diane R Gold$19,628,221
- Pinghui Feng$20,425,150
Others in their field
Top investigators on “Macaca Mulatta”
- Barton F Haynes · Duke University$291,595,855
- Peter Gordon Gillespie · Oregon Health And Science University$83,402,374
- Richard A Gibbs · Baylor College Of Medicine$82,928,769
- Dan H. Barouch · Fred Hutchinson Cancer Center$67,567,747
- David I Watkins · George Washington University$57,087,952
- Rama Rao Amara · Emory University$54,145,017
Research focus
Macaca MulattaAntibodiesMonkeysInfectionFundingGrantHiv-1BaseVectorVirusAcquired Immunodeficiency SyndromeVaccinesUnited States National Institutes Of HealthResearch StudySourceVariantNeutralizing AntibodyHerpesviridaeResourcesRecombinantsImmunityImmune ResponseAdeno-Associated Viral VectorRhadinovirus
Grant awards (155)
Project 2: Limiting anti-drug antibodies$873,853
U19 · FY2024 · AI · contact PI
Functional Role of O-glycosylation of HIV-1$441,997
R01 · FY2024 · AI · contact PI
Functional Role of O-glycosylation of HIV-1$446,602
R01 · FY2023 · AI · contact PI
Project 2: Limiting anti-drug antibodies$403,000
U19 · FY2023 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$583,538
R37 · FY2022 · AI · contact PI
Functional Role of O-glycosylation of HIV-1$448,137
R01 · FY2022 · AI · contact PI
Project 2: Limiting anti-drug antibodies$316,183
U19 · FY2022 · AI · contact PI
Project 2: Limiting anti-drug antibodies$1,122,917
U19 · FY2021 · AI · contact PI
Immunoglobulins Delivered by AVV Vector for the Prevention of SIV Infection$731,021
R01 · FY2021 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$583,538
R37 · FY2021 · AI · contact PI
Functional Role of O-glycosylation of HIV-1$447,970
R01 · FY2021 · AI · contact PI
Immunoglobulins Delivered by AVV Vector for the Prevention of SIV Infection$731,021
R01 · FY2020 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$583,538
R37 · FY2020 · AI · contact PI
Functional Role of O-glycosylation of HIV-1$461,012
R01 · FY2020 · AI · contact PI
Project 2: Limiting anti-drug antibodies$405,000
U19 · FY2020 · AI · contact PI
Immunoglobulins Delivered by AVV Vector for the Prevention of SIV Infection$731,021
R01 · FY2019 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$583,538
R37 · FY2019 · AI · contact PI
Immunoglobulins Delivered by AVV Vector for the Prevention of SIV Infection$731,021
R01 · FY2018 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$583,538
R37 · FY2018 · AI · contact PI
Immunoglobulins Delivered by AVV Vector for the Prevention of SIV Infection$731,021
R01 · FY2017 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$530,253
R37 · FY2017 · AI · contact PI
Functional Role of O-Glycosylation of HIV-1$383,750
R01 · FY2017 · AI · contact PI
Therapuetic effector functions of AAV-expressed transgenes$870,577
P01 · FY2016 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$530,253
R37 · FY2016 · AI · contact PI
Functional Role of O-Glycosylation of HIV-1$383,750
R01 · FY2016 · AI · contact PI
Therapuetic effector functions of AAV-expressed transgenes$878,155
P01 · FY2015 · AI · contact PI
Immunoglobulins Delivered by AAV Vector for the Prevention of SIV Infection$710,565
R01 · FY2015 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$530,253
R37 · FY2015 · AI · contact PI
Immunoglobulins Delivered by AAV Vector for the Prevention of SIV Infection$418,174
U19 · FY2015 · AI · contact PI
Functional Role of O-Glycosylation of HIV-1$383,750
R01 · FY2015 · AI · contact PI
Therapuetic effector functions of AAV-expressed transgenes$872,628
P01 · FY2014 · AI · contact PI
Immunoglobulins Delivered by AAV Vector for the Prevention of SIV Infection$710,565
R01 · FY2014 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$530,253
R37 · FY2014 · AI · contact PI
Immunoglobulins Delivered by AAV Vector for the Prevention of SIV Infection$433,428
U19 · FY2014 · AI · contact PI
Functional Role of O-Glycosylation of HIV-1$383,750
R01 · FY2014 · AI · contact PI
Therapuetic effector functions of AAV-expressed transgenes$756,630
P01 · FY2013 · AI · contact PI
Immunoglobulins Delivered by AAV Vector for the Prevention of SIV Infection$667,931
R01 · FY2013 · AI · contact PI
Immunoglobulins Delivered by AAV Vector for the Prevention of SIV Infection$575,981
U19 · FY2013 · AI · contact PI
Functional Role of O-Glycosylation of HIV-1$314,577
R01 · FY2013 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$240,000
R01 · FY2013 · AI · contact PI
Functional Role of O-Glycosylation of HIV-1$52,612
R01 · FY2013 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$27,306
R37 · FY2013 · AI · contact PI
Immunoglobulins Delivered by AAV Vector for the Prevention of SIV Infection$810,091
R01 · FY2012 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$604,524
R56 · FY2012 · AI · contact PI
Therapuetic effector functions of AAV expressed transgenes$436,723
P01 · FY2012 · AI · contact PI
Immunoglobulins Delivered by AAV Vector for the Prevention of SIV Infection$422,627
U19 · FY2012 · AI · contact PI
Rhesus Monkey Rhadinovirus Glycoproteins, Entry, and Neutralization$382,607
R01 · FY2012 · AI · contact PI
Contribution of anti-env immune responses to protection by live attenuated SIV$569,148
P01 · FY2011 · AI · contact PI
Immunoglobulins Delivered by AAV Vector for the Prevention of SIV Infection$438,780
U19 · FY2011 · AI · contact PI
Rhesus Monkey Rhadinovirus Glycoproteins, Entry, and Neutralization$382,607
R01 · FY2011 · AI · contact PI
USE OF ADENO-ASSOCIATED VIRUS TO DELIVER ANTIBODIES WITH NEUTRALIZING ACTIVITY$210,597
P51 · FY2011 · RR · contact PI
MEMBRANE SPANNING REGIONS AS PROTEIN-PROTEIN INTERACTING DOMAINS IN HIV$210,597
P51 · FY2011 · RR · contact PI
GAMMA-2 HERPESVIRUS AS VACCINE VECTORS FOR AIDS$210,597
P51 · FY2011 · RR · contact PI
IMPROVED REAGENTS FOR AIDS VACCINE AND PATHOGENESIS RESEARCH$210,597
P51 · FY2011 · RR · contact PI
IDENTIFICATION OF ANTI-SIV MONOCLONAL ANTIBODIES WITH NEUTRALIZING ACTIVITY$210,597
P51 · FY2011 · RR · contact PI
STRATEGIES OF IMMUNE EVASION IN AIDS$210,597
P51 · FY2011 · RR · contact PI
MONKEY RHADINOVIRUS, A MONKEY MODEL FOR HUMAN HERPESVIRUS 8$210,597
P51 · FY2011 · RR · contact PI
LIVE ATTENUATED VACCINE APPROACHES FOR AIDS$210,597
P51 · FY2011 · RR · contact PI
MICROBIOLOGICAL REAGENT AND SAMPLE DISTRIBUTION$210,597
P51 · FY2011 · RR · contact PI
Contribution of anti-env immune responses to protection by live attenuated SIV$597,735
P01 · FY2010 · AI · contact PI
Molecular Basis for SIV Pathogenicity$398,429
R01 · FY2010 · AI · contact PI
Rhesus Monkey Rhadinovirus Glycoproteins, Entry, and Neutralization$386,471
R01 · FY2010 · AI · contact PI
IDENTIFICATION OF ANTI-SIV MONOCLONAL ANTIBODIES WITH NEUTRALIZING ACTIVITY$202,435
P51 · FY2010 · RR · contact PI
USE OF ADENO-ASSOCIATED VIRUS TO DELIVER ANTIBODIES WITH NEUTRALIZING ACTIVITY$202,435
P51 · FY2010 · RR · contact PI
STRATEGIES OF IMMUNE EVASION IN AIDS$202,435
P51 · FY2010 · RR · contact PI
LIVE ATTENUATED VACCINE APPROACHES FOR AIDS$202,435
P51 · FY2010 · RR · contact PI
MICROBIOLOGICAL REAGENT AND SAMPLE DISTRIBUTION$202,435
P51 · FY2010 · RR · contact PI
MONKEY RHADINOVIRUS, A MONKEY MODEL FOR HUMAN HERPESVIRUS 8$202,435
P51 · FY2010 · RR · contact PI
GAMMA-2 HERPESVIRUS AS VACCINE VECTORS FOR AIDS$202,435
P51 · FY2010 · RR · contact PI
IMPROVED REAGENTS FOR AIDS VACCINE AND PATHOGENESIS RESEARCH$202,435
P51 · FY2010 · RR · contact PI
Contribution of anti-env immune responses to protection by live attenuated SIV$794,348
P01 · FY2009 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$651,561
R01 · FY2009 · AI · contact PI
Molecular Basis for SIV Pathogenicity$402,453
R01 · FY2009 · AI · contact PI
Rhesus Monkey Rhadinovirus Glycoproteins, Entry, and Neutralization$390,375
R01 · FY2009 · AI · contact PI
STRATEGIES OF IMMUNE EVASION IN AIDS$206,081
P51 · FY2009 · RR · contact PI
LIVE ATTENUATED VACCINE APPROACHES FOR AIDS$206,081
P51 · FY2009 · RR · contact PI
MONKEY RHADINOVIRUS, A MONKEY MODEL FOR HUMAN HERPESVIRUS 8$206,081
P51 · FY2009 · RR · contact PI
STRATEGIES OF IMMUNE EVASION IN AIDS$206,081
P51 · FY2009 · RR · contact PI
STRATEGIES OF IMMUNE EVASION IN AIDS$206,081
P51 · FY2009 · RR · contact PI
MICROBIOLOGICAL REAGENT AND SAMPLE DISTRIBUTION$206,081
P51 · FY2009 · RR · contact PI
Contribution of anti-env immune responses to protection by live attenuated SIV$776,974
P01 · FY2008 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$498,084
R01 · FY2008 · AI · contact PI
Molecular Basis for SIV Pathogenicity$402,453
R01 · FY2008 · AI · contact PI
Rhesus Monkey Rhadinovirus Glycoproteins, Entry, and Neutralization$390,375
R01 · FY2008 · AI · contact PI
STRATEGIES OF IMMUNE EVASION IN AIDS$135,175
P51 · FY2008 · RR · contact PI
MICROBIOLOGICAL REAGENT AND SAMPLE DISTRIBUTION$135,175
P51 · FY2008 · RR · contact PI
LIVE ATTENUATED VACCINE APPROACHES FOR AIDS$135,175
P51 · FY2008 · RR · contact PI
Contribution of anti-env immune responses to protection by live attenuated SIV$751,187
P01 · FY2007 · AI · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$492,941
R01 · FY2007 · AI · contact PI
Molecular Basis for SIV Pathogenicity$410,248
R01 · FY2007 · AI · contact PI
MICROBIOLOGICAL REAGENT AND SAMPLE DISTRIBUTION$107,540
P51 · FY2007 · RR · contact PI
AIDS PATHOGENESIS$107,540
P51 · FY2007 · RR · contact PI
MONKEY RHADINOVIRUS, A MONKEY MODEL FOR HUMAN HERPESVIRUS 8$58,487
P51 · FY2007 · RR · contact PI
FACILITIES OPERATIONS FOR AIDS RELATED RESEARCH$859,000
P51 · FY2006 · RR · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$492,875
R01 · FY2006 · AI · contact PI
Molecular Basis for SIV Pathogenicity$422,500
R01 · FY2006 · AI · contact PI
LIVE ATTENUATED VACCINE APPROACHES FOR AIDS$134,807
P51 · FY2006 · RR · contact PI
MODULATION OF ENV CONTENT IN VIRIONS OF SIV$134,807
P51 · FY2006 · RR · contact PI
MICROBIOLOGICAL REAGENT AND SAMPLE DISTRIBUTION$134,807
P51 · FY2006 · RR · contact PI
RHESUS MONKEY RHADINOVIRUS, A MONKEY MODEL FOR HUMAN HERPESVIRUS 8$55,933
P51 · FY2006 · RR · contact PI
Gamma-2 Herpesviruses as Vaccine Vectors for AIDS$490,034
R01 · FY2005 · AI
MOLECULAR BASIS FOR STV PATHOGENICITY$456,405
R37 · FY2005 · AI
Contributions of HIV qp41 TM Protein to Pathogenesis$382,500
R01 · FY2005 · AI
Monkey model for KSHV in the oral cavity$272,906
P01 · FY2005 · DE
STRATEGIES OF IMMUNE EVASION IN AIDS$85,837
P51 · FY2005 · RR
LIVE ATTENUATED VACCINE APPROACHES FOR AIDS$85,837
P51 · FY2005 · RR
MODULATION OF ENV CONTENT IN VIRIONS OF SIV$85,837
P51 · FY2005 · RR
MICROBIOLOGICAL REAGENT AND SAMPLE DISTRIBUTION$69,059
P51 · FY2005 · RR
LIVE ATTENUATED MULTIPLY DELETED HIV1 VACCINE FOR AIDS$1,995,113
P01 · FY2004 · AI
MOLECULAR BASIS FOR STV PATHOGENICITY$443,111
R37 · FY2004 · AI
Contributions of HIV qp41 TM Protein to Pathogenesis$382,500
R01 · FY2004 · AI
Monkey model for KSHV in the oral cavity$264,959
P01 · FY2004 · DE
MODULATION OF ENV CONTENT IN VIRIONS OF SIV$80,214
P51 · FY2004 · RR
IMMUNE EVASION IN AIDS: RESISTANCE TO NEUTRALIZING ABS$80,214
P51 · FY2004 · RR
LIVE ATTENUATED VACCINE APPROACHES FOR AIDS$80,214
P51 · FY2004 · RR
MICROBIOLOGICAL REAGENT AND SAMPLE DISTRIBUTION$80,214
P51 · FY2004 · RR
SINGLE CYCLE SIV$80,214
P51 · FY2004 · RR
HERPESVIRUSES AS VACCINE VEHICLES FOR AIDS$80,214
P51 · FY2004 · RR
MOLECULAR BASIS FOR STV PATHOGENICITY$430,205
R37 · FY2003 · AI
Contributions of HIV qp41 TM Protein to Pathogenesis$382,500
R01 · FY2003 · AI
Monkey model for KSHV in the oral cavity$252,450
P01 · FY2003 · DE
ANIMAL MODEL DEVELOPMENT: SHIVRT$237,176
P51 · FY2003 · RR
RECOMBINANT SALMONELLA AS A VACCINE VEHICLE FOR AIDS$237,176
P51 · FY2003 · RR
SINGLE CYCLE SIV$237,176
P51 · FY2003 · RR
MICROBIOLOGICAL REAGENT AND SAMPLE DISTRIBUTION$237,176
P51 · FY2003 · RR
STRATEGIES OF IMMUNE EVASION IN AIDS: DISPENSABILITY OF V1-V2$237,176
P51 · FY2003 · RR
SAFETY OF NEF-DELETED SIV$237,176
P51 · FY2003 · RR
STRATEGIES OF IMMUNE EVASION IN AIDS: ROLE OF B CELLS$237,157
P51 · FY2003 · RR
CELLULAR PARTNERS FOR CYTOPLASMIC DOMAIN OF TRANSMEMBRANE PROTEIN OF SIV &HIV$237,157
P51 · FY2003 · RR
PERSISTENT HERPESVIRUSES AS VACCINE VEHICLES FOR AIDS$237,154
P51 · FY2003 · RR
LIVE ATTENUATED MULTIPLY DELETED HIV1 VACCINE FOR AIDS$2,135,845
P01 · FY2002 · AI
MOLECULAR BASIS FOR STV PATHOGENICITY$417,675
R37 · FY2002 · AI
Contributions of HIV qp41 TM Protein to Pathogenesis$382,500
R01 · FY2002 · AI
Monkey model for KSHV in the oral cavity$252,450
P01 · FY2002 · DE
IDENTIFICATION OF HIGHLY ATTENUATED MUTANTS OF SIMIAN IMMUNODEFICIENCY VIRUS$111,112
P51 · FY2002 · RR
HERPES VIRUS VECTORS AS VACCINES$0
P01 · FY2002 · AI
CORE--SCIENTIFIC CORE$0
P01 · FY2002 · AI
PROTECTIVE EFFICACY OF LIVE ATTENUATED SIV VACCINES$0
P01 · FY2002 · AI
LIVE ATTENUATED MULTIPLY DELETED HIV1 VACCINE FOR AIDS$2,158,944
P01 · FY2001 · AI
MOLECULAR BASIS FOR STV PATHOGENICITY$405,510
R37 · FY2001 · AI
Contributions of HIV qp41 TM Protein to Pathogenesis$327,038
R01 · FY2001 · AI
Monkey model for KSHV in the oral cavity$252,450
P01 · FY2001 · DE
IDENTIFICATION OF HIGHLY ATTENUATED MUTANTS OF SIMIAN IMMUNODEFICIENCY VIRUS$111,112
P51 · FY2001 · RR
19th Annual Symposium-Nonhuman Primate Models for AIDS$48,729
R13 · FY2001 · RR
PROTECTIVE EFFICACY OF LIVE ATTENUATED SIV VACCINES$0
P01 · FY2001 · AI
CORE--PRIMATE$0
P30 · FY2001 · AI
HERPES VIRUS VECTORS AS VACCINES$0
P01 · FY2001 · AI
CORE--SCIENTIFIC CORE$0
P01 · FY2001 · AI
LIVE ATTENUATED MULTIPLY DELETED HIV1 VACCINE FOR AIDS$2,168,168
P01 · FY2000 · AI
CORE--SCIENTIFIC CORE$448,605
P01 · FY2000 · AI
PROTECTIVE EFFICACY OF LIVE ATTENUATED SIV VACCINES$448,605
P01 · FY2000 · AI
MOLECULAR BASIS FOR SIV PATHOGENICITY$362,716
R37 · FY2000 · AI
HERPES VIRUS VECTORS AS VACCINES$279,635
P01 · FY2000 · AI
CORE--PRIMATE$116,830
P30 · FY2000 · AI
EXPERIMTL INFECTION OF RHESUS &PIG TAILED MACAQUES W/ RHADINOVIRUSES: KS MODEL$96,192
P51 · FY2000 · RR